MipSalus develops treatments for severe, rare amino acid metabolism disorders. First drug in our pipeline is Phelimin for the treatment of Phenylketonuria, PKU. Phelimin is an oral, non-systemic drug that will allow PKU patients to eat normal food and live normal lives. Phelimin has received orphan drug designations from both EMA and FDA. 

Our medicinal products are based on our proprietary Molecular Imprinted Polymers (MIP) technology platform. We use MIPs to bind specific pathogenic amino acids in the gastrointestinal tract. 

The name “MipSalus” is a combination of MIP and “Salus” which is the name of the ancient Roman goddess of health and prosperity. In other words; MipSalus’ mission is to use the MIPs technology for healthcare purposes. 

To ensure optimal efficiency and flexibility MipSalus is a slim core organization supplemented with close collaboration with relevant private subcontractors and universities. 

MipSalus ApS was founded in 2006 and funded solely by private investors.

MipSalus ApS

Nicolas Krogh

This department focuses on advancing scientific research and developing innovative solutions to drive the organization forward.

MipSalus ApS

Org chart

Teams

Research and Development

Offices